# A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.

> **NCT02920242** · PHASE3 · TERMINATED · sponsor: **Sandoz** · enrollment: 28 (actual)

## Conditions studied

- Travelers' Diarrhea

## Interventions

- **DRUG:** Rifaximin (Sandoz GmbH) tablet
- **DRUG:** Rifaximin (Xifaxan)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02920242
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-15
- **Primary completion:** 2017-05-23
- **Final completion:** 2017-05-23
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Terminated due to low enrollment
- **Last updated:** 2019-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920242, "A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02920242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*